NO20090788L - Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase - Google Patents

Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase

Info

Publication number
NO20090788L
NO20090788L NO20090788A NO20090788A NO20090788L NO 20090788 L NO20090788 L NO 20090788L NO 20090788 A NO20090788 A NO 20090788A NO 20090788 A NO20090788 A NO 20090788A NO 20090788 L NO20090788 L NO 20090788L
Authority
NO
Norway
Prior art keywords
treatment
tyrosine kinase
ret
receptor tyrosine
ret receptor
Prior art date
Application number
NO20090788A
Other languages
English (en)
Norwegian (no)
Inventor
Anderson Joseph Ryan
James Sherwood
Alan Wookey
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20090788L publication Critical patent/NO20090788L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20090788A 2006-09-07 2009-02-19 Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase NO20090788L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84276606P 2006-09-07 2006-09-07
PCT/GB2007/003335 WO2008029123A1 (en) 2006-09-07 2007-09-06 Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase

Publications (1)

Publication Number Publication Date
NO20090788L true NO20090788L (no) 2009-03-13

Family

ID=38829617

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090788A NO20090788L (no) 2006-09-07 2009-02-19 Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase

Country Status (12)

Country Link
US (1) US20110028498A1 (pt)
EP (1) EP2064340A1 (pt)
JP (1) JP2010502209A (pt)
KR (1) KR20090048644A (pt)
CN (1) CN101512017A (pt)
AU (1) AU2007293280A1 (pt)
BR (1) BRPI0716555A2 (pt)
CA (1) CA2662591A1 (pt)
IL (1) IL197157A0 (pt)
MX (1) MX2009002471A (pt)
NO (1) NO20090788L (pt)
WO (1) WO2008029123A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
JP6038128B2 (ja) * 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN103930571A (zh) * 2011-11-17 2014-07-16 瑞尼克斯有限公司 用于选择性分子分析的系统和方法
MX2014013806A (es) * 2012-05-14 2014-11-26 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
EP3470513B1 (en) * 2013-03-15 2020-05-13 Expression Pathology, Inc. Srm assay to indicate cancer therapy
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
JP6130755B2 (ja) * 2013-08-12 2017-05-17 ルネサスエレクトロニクス株式会社 半導体装置およびその製造方法
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
WO2017134115A1 (en) * 2016-02-01 2017-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for determining responsiveness to vandetanib in a patient suffering from medullary thyroid carcinoma
JP7280823B2 (ja) * 2016-11-30 2023-05-24 エクソサム ダイアグノスティクス,インコーポレイティド 非小細胞肺癌患者由来のエクソソームrna及び無細胞dnaを使用して血漿中の変異を検出するための方法と組成物
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CN109439752B (zh) * 2018-11-16 2022-02-15 上海派森诺医学检验所有限公司 一种鉴别甲状腺髓样癌ret基因突变的特异性引物组合及其试剂盒及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
ITMI20021620A1 (it) * 2002-07-23 2004-01-23 Novuspharma Spa Composto ad ativita' antitumorale

Also Published As

Publication number Publication date
CN101512017A (zh) 2009-08-19
EP2064340A1 (en) 2009-06-03
MX2009002471A (es) 2009-03-20
IL197157A0 (en) 2009-11-18
WO2008029123A1 (en) 2008-03-13
BRPI0716555A2 (pt) 2013-09-24
AU2007293280A1 (en) 2008-03-13
JP2010502209A (ja) 2010-01-28
CA2662591A1 (en) 2008-03-13
KR20090048644A (ko) 2009-05-14
US20110028498A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
NO20090788L (no) Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase
EA200901550A1 (ru) Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений
NO20056236L (no) Behandling med anti-VEGF-antistoffer
BRPI0908026B8 (pt) uso de rifaximina no tratamento de doenças do intestino
WO2009019230A3 (en) Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease
CY1119513T1 (el) Μεθοδοι και συνθεσεις για την διαγνωση και την θεραπευτικη αγωγη δευτερογενους αυτοανοσης νοσου της πολλαπλης σκληρυνσης
NO20070521L (no) Fremgangsmater relatert til en enkel nukleotid polymorfisme av den G-proteinkoplede reseptor, GPR40
WO2012009382A3 (en) Molecular indicators of bladder cancer prognosis and prediction of treatment response
WO2009133197A3 (en) Levels of april in serum and use in diagnostic methods
WO2010116003A3 (en) Method for predicting the response of non-small cell lung cancer patients to targeted pharmacotherapy
WO2017167942A8 (en) Method for predicting the response of melanoma patients to a medicament
Regensburger et al. Motor and non-motor fluctuations in Parkinson’s disease: the knowns and unknowns of current therapeutic approaches
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
NO330943B1 (no) En metode for detektering og/eller typebestemmelse og/eller kvantifisering av human papillomavirus (HPV) type, primere og prober derav samt diagnostisk sett og anvendelse derav.
WO2009004914A1 (ja) フッ素およびヒドロキシ基で置換されたアルコキシ基を有するpetプローブ
EP1962674A4 (en) IMPLANTABLE MEDICINE PRODUCT WITH STATUS REPORT
WO2009016231A3 (en) Compositions and methods for detecting histamine related disorders
WO2007085958A3 (en) Diagnosis, prognosis and screening for medicaments for treatment of myeloproliferative disorders using receptor protein tyrosine-phosphatase gamma (ptprg) as biomarker
WO2006046270A3 (en) Nucleophosmin protein (npm) mutants, corresponding gene sequences and uses thereof
WO2010148323A3 (en) Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus-related virus
두건문 The risk factors, diagnosis and treatment guideline of erectile dysfunction
ATE529750T1 (de) Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target
WO2017059276A8 (en) Therapeutic and diagnostic methods for autoimmune diseases and/or inflammation
Ettala et al. Erectile dysfunction cannot be used in primary screening of pre-diabetes
Raij et al. Office and Ambulatory Blood Pressure–Lowering Effects of Combination Valsartan/Hydrochlorothiazide vs Hydrochlorothiazide‐Based Therapy in Obese, Hypertensive Patients

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application